Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential and financial performance, leading to a significant drop in stock price [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 9, 2024, to May 8, 2025 [3]. - Allegations include that Iovance made overwhelmingly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [3]. - The company announced reduced revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [3]. Financial Impact - Following the announcement of reduced guidance, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case [4]. Law Firm Information - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors from deceit and fraud [5].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential while failing to meet revenue expectations, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations - The lawsuit claims that during the class period from May 9, 2024, to May 8, 2025, Iovance made overly positive statements while concealing material adverse facts about its ability to generate demand for its treatments [1]. - The company announced a reduction in revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace in treatment initiation [1]. Financial Impact - Following the announcement of lowered guidance, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.795% in one day [1]. Next Steps for Shareholders - Shareholders who purchased IOVA shares during the specified class period are encouraged to register for the class action by July 14, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines to treat patients and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements about the company's growth potential and operational capabilities [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Iovance to contact them to discuss their legal options, particularly in light of a federal securities class action with a deadline of July 14, 2025, for seeking the role of lead plaintiff [1][2]. - The complaint against Iovance alleges that the company and its executives made false or misleading statements and failed to disclose the true state of the company's growth potential [4]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced its second-quarter financial results for fiscal 2024 and reduced its revenue guidance for the full year, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation [5]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [5].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient selection [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance due to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - Following the announcement of poor financial results on May 8, 2025, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. for alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential and ability to meet demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Iovance Biotherapeutics, Inc. faces a class action lawsuit following a significant decline in its financial performance and revenue guidance, leading to a sharp drop in its stock price [1][2][3]. Financial Performance - For Q1 2025, Iovance reported total product revenue of $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of approximately 33% [2]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2]. Lawsuit Details - The class action lawsuit alleges that Iovance made materially false and misleading statements regarding its business operations and prospects during the class period [3]. - Specific allegations include delays in new Authorized Treatment Centers (ATCs) beginning patient treatments, inefficiencies in patient identification and selection, and resulting higher costs and lower revenues due to ATCs not keeping pace with manufactured products [3]. Legal Action - Investors who purchased Iovance securities during the class period have until July 14, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Company Performance and Allegations - The lawsuit claims that Iovance provided overly positive statements while concealing material adverse facts about its growth potential, specifically its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Legal Proceedings - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [3]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4].

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=150973&from=3 C ...